ADB International Group (OTCMKTS:EQUR – Get Free Report) and Enovis (NYSE:ENOV – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Valuation & Earnings
This table compares ADB International Group and Enovis”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ADB International Group | N/A | N/A | N/A | N/A | N/A |
| Enovis | $2.25 billion | 0.63 | -$1.18 billion | ($19.26) | -1.27 |
Profitability
This table compares ADB International Group and Enovis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ADB International Group | N/A | N/A | N/A |
| Enovis | -47.96% | 12.03% | 4.91% |
Insider and Institutional Ownership
98.5% of Enovis shares are owned by institutional investors. 79.6% of ADB International Group shares are owned by company insiders. Comparatively, 2.9% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current recommendations for ADB International Group and Enovis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ADB International Group | 0 | 0 | 0 | 0 | 0.00 |
| Enovis | 1 | 1 | 8 | 0 | 2.70 |
Enovis has a consensus target price of $42.00, suggesting a potential upside of 71.88%. Given Enovis’ stronger consensus rating and higher possible upside, analysts plainly believe Enovis is more favorable than ADB International Group.
Summary
Enovis beats ADB International Group on 7 of the 9 factors compared between the two stocks.
About ADB International Group
E-Qure Corp., a medical device company, focuses on the development and commercialization of bioelectrical signal therapy (BST) devices. Its BST devices implement patented and proprietary electrical stimulation technologies to treat hard-to-cure wounds and ulcers up to complete closure and/or cure. The company was incorporated in 1988 and is based in New York, New York.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
Receive News & Ratings for ADB International Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADB International Group and related companies with MarketBeat.com's FREE daily email newsletter.
